Torsades de Pointes
-
Subject Areas on Research
- A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
- Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation.
- Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
- Antipsychotic medications and sudden cardiac death.
- Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.
- Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
- Dofetilide dose reductions and discontinuations in women compared with men.
- Evaluation of the dofetilide risk-management program.
- Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
- Frequency of high-risk use of QT-prolonging medications.
- Images in clinical medicine. Internal ventricular defibrillation.
- Improving the assessment of heart toxicity for all new drugs through translational regulatory science.
- Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
- Moxifloxacin-induced torsades de pointes.
- Potassium channel blockade amplifies cardiac instability numerical studies of torsades de pointes.
- Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
- Pro: The Food and Drug Administration Black box warning on droperidol is not justified.
- QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
- QTc monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the Association of Medicine and Psychiatry.
- Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
- Safety of patients reason for FDA black box warning on droperidol.
- Torsades de pointes associated with fluoroquinolones.
- Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease.
- What clinicians should know about the QT interval.
-
Keywords of People
- Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine